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Summary 
Considerable controversy and uncertainty have surrounded the biological function of the Human 
Immunodeficiency Virus (HIV)-I  nef gene product.  Initial studies suggested that  this early, 
nonstructural viral protein functioned as a negative regulatory factor; thus, it was proposed to 
play  a  role  in  establishing  or  maintaining  viral  latency.  In  contrast,  studies  in  Simian 
Immunodeficiency Virus  (SIV)mac-infected rhesus monkeys have suggested that  Nef is not  a 
negative factor but rather plays a central role in promoting high-level viral replication and is 
required for viral pathogenesis in vivo. We sought to define a tissue culture system that would 
approximate the in vivo setting for virus infection in order to assess the role of HIV-1 Nef in 
viral replication. We show that infection of mitogen-activated peripheral blood mononuclear 
cells (PBMC) with Nef  + HIV results in enhanced replication as evidenced by earlier gag  p24 
expression when compared with infections performed with nefmutant viruses.  Moreover, when 
unstimulated  freshly  isolated  PBMC  are  infected with  Nef  +  and  Nef-  viruses  and  then 
subsequently activated with mitogen, the Nef-induced difference in viral replication kinetics is 
even  more  pronounced,  with  the  Nef-  viruses  requiring  much  more  time  in  culture  for 
appreciable growth. A positive effect of Nef on viral replication was also observed in primary 
macrophages infected with  a recombinant of YU-2,  a patient-derived molecular clone with 
macrophage tropism. These positive effects of Nef on viral replication are dependent on the initial 
multiplicity of infection (MOI), in that infections of unstimulated PBMC at low MOI are most 
dependent upon intact neffor subsequent viral growth. We now provide evidence that the Nef  § 
HIV is more infectious than Nef- HIV from both a tissue culture infectious dose analysis, and 
a single-cell HIV infection assay. In the latter case, we demonstrate that infection with equivalent 
doses of HIV based on virion-associated gag p24 yields five- to sixfold more infected cells if 
Nef  +  viral  stocks  were used.  Furthermore,  we  find  that  the  differential infectivity is  not 
dependent on CD4 down-regulation as Nef  + virus produced from transfected COS cells lacking 
CD4 is also more infectious.  However, normalization of PBMC infections to equivalent infectivity 
between that of the Nef  + and Nef- viruses continues to reveal delayed viral replication in the 
absence of Nef,  suggesting  that  secondary viral  spread in PBMC  is  also  enhanced in  Nef  + 
infections. We demonstrate this directly by showing a 13-15-fold increase in infectivity of PBMC- 
derived Nef  + HIV.  In summary, these findings demonstrate a consistent positive role for the 
HIV-1 nef gene in promoting viral infection and replication, and suggest that the basis for this 
phenotype is the increased infectivity of HIV produced from cells expressing nef.  These data 
suggest that HIV-1 Nef, as previously shown for SIV Nef, may play an important role in establishing 
a fulminant form of viral infection in vivo. 
T 
he HIV-1 nefgene is located at the 3' end of the viral 
genome, partially overlapping the U3 region of the 3' 
LTR. Nef is expressed early in the HIV replication cycle from 
multiply spliced mRNA  transcripts  that  encode a 27-kD 
myristylated protein that is largely membrane associated (1-5). 
Interestingly, up to 80%  of the early viral transcripts can 
encode Nef, suggesting an early function for the nef gene 
product (6). This gene was named nefbecause  the earliest 
studies suggested that it behaved as a negative regulatory factor, 
suppressing both viral replication and transcriptional activity 
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lated that Nef might function to establish viral latency after 
infection. However, other investigations failed to confirm these 
negative effects of Nef (5,  11). In fact, Kim et al. (11) ob- 
served that infection of activated CD4 § T lymphocytes with 
a  Nef  §  viral strain resulted in moderately enhanced viral 
replication as compared with a nefmutant. Additionally, the 
mechanistically intriguing observation that Nef both binds 
GTP  and exhibits GTPase  activity (12) was  subsequently 
refuted by three different laboratories  employing purified Nef 
protein isolated from both bacterial and insect sources (13-15). 
Perhaps  the only property of Nef that is not in dispute is 
its inhibitory effect on cell surface CD4 expression.  This has 
been demonstrated in multiple cell lines stably or transiently 
expressing HIV nef(16-18), and has recently been shown for 
SIV nefas well (19). Although these authors have shown that 
CD4 down-regulation provides  resistance  to superinfection 
with SIV in vitro (19), the in vivo significance of this biolog- 
ical effect of Nef remains to be established. 
Thus, the in vitro analyses of HIV-1 Nef to date have pro- 
duced no uniform insights into its biological function or 
significance in the viral life cycle. In fact, tissue culture HIV-1 
isolates often develop mutations within nefwith no apparent 
adverse  effect on their replication in various tissue culture 
cell lines (20).  In 1991, Kestler et al. (21) described intrig- 
uing results in the SIVmac/rhesus monkey model system of 
AIDS that emphasized an in vivo significance for nef. Three 
major findings emerged from this work: (a) animals infected 
with SIVmac  containing a point mutation within nefrapidly 
reverted back to wild type nefin  vivo; (b) animals infected 
with a nef-deleted virus demonstrated a dramatically reduced 
virus load in their PBMC; and (c) the same nef-deleted virus- 
infected animals did not develop any AIDS pathology. More 
recently, the animals infected with  the nef-deleted  SlVmac 
have been shown to be protected from challenge with a high 
dose of live wild type SlVmac (22).  Together, these findings 
highlight the in vivo importance of the nefgene product in 
viral pathogenesis and suggest that the nefgene functions 
as a positive regulatory factor that is essential for high-level 
viral replication in vivo. 
In this report we demonstrate that HIV-1 Nef acts to dra- 
matically accelerate the replication kinetics of HIV-1 in pri- 
mary human PBMC that are infected directly after isolation 
from normal donors and subsequently lectin-activated in vitro. 
We also show that HIV-1 nefcontributes to increased repli- 
cation in primary macrophages. Finally, we show that the 
infectivity of HIV containing intact nefis enhanced in both 
a  tissue  culture  infectious dose  (TCID50) 1 analysis  and  a 
single-cell infection assay. These observations establish a posi- 
tive role for HIV-1 nefin the viral life cycle and suggest that 
the basis for the increased replication kinetics of Nef  + HIV 
is the increased infectivity of viral particles.  The tissue cul- 
1 Abbreviations used in  this paper: fs, frameshift; MOI, multiplicity  of 
infection;  TCIDs0, tissue  culture infectious  dose of 50% infectivity;  TEN, 
Tris-C1/EDTA/NaC1. 
ture-based assay systems described provide for future investi- 
gations into the precise biological mechanism of Nef-mediated 
enhancement of  HIV infection and replication in primary cells. 
Materials and Methods 
Cell Lysates and Western Blots.  8 x  106 COS-7 cells were trans- 
fected with 10 #g of HIV proviral DNA (see Fig. 1 a) by elec- 
troporation at 240 V and 960/zF using the Bio-Rad Gene Pulser 
(Richmond, CA). A mock transfection  was done by electroporating 
cells in media alone. The cells were cultured for 2 d in Iscove's Com- 
plete Medium (Mediatech, Washington, DC) containing 10% FBS 
(GIBCO  BRL, Gaithersburg, MD),  100 U/ml penicillin/strep- 
tomycin (pen/strep), and 2 mM L-glutamine  (both from Mediatech). 
The cell layer was washed twice with Mg  2+, Ca  2+ free PBS. The 
cells were removed from the flask by a 10-rain incubation in TEN 
(40 mM Tris-C1, pH 7.5, 1 mM EDTA, pFl 8.0, 150 mM NaC1) 
with agitation. The ceUs were pelleted and washed once with ad- 
ditional TEN. The cell pellet was resuspended  in 0.6 ml TEN lysis 
buffer (TEN plus 1% Triton X-100 and 1 mM PMSF). The cells 
were centrifuged again, and the soluble portion retrieved and stored 
at  -70~  The cell pellets were discarded. 
Approximately 25/zg of the cell extracts was run on 10% poly- 
acrylamide  gels containing 0.1% SDS along with Rainbow molec- 
ular weight standards (Amersham Corp., Arlington Heights, IL) 
and then transferred onto nitrocellulose (Schleicher and Schuell, 
Inc., Keene, NH). The blots were blocked overnight in 5% nonfat 
dry milk and 0.1% Tween-20 in PBS. The blocking solution also 
served as the primary antibody diluent. One blot was incubated 
in 17.6 I~g/ml of an HIV-1 BH10 anti-Nef monoclonal antibody 
obtained from the National Institutes of Health AIDS Research 
and Reference  Reagent Program (Cat. #456) (13) for 1 h. A second 
blot was incubated for 1 h in a pool of four human HIV patient 
antisera each diluted to 1:400. Both blots were incubated in horse- 
radish peroxidase-conjugated  sheep anti-human or anti-mouse Ig 
(Amersham Corp.) diluted  at 1:2500 in PBS containing  0.1% Tween- 
20. All incubations were carried out at room temperature, and the 
blots were extensively  washed between incubations with PBS con- 
taining 0.1% Tween-20. Immunoreactive bands were visualized 
using the ECL Detection System (Amersham Corp.). 
Virus Stocks.  10/zg of plasmid containing the HIV proviral 
DNA was transfected into 15  x  106 C05-7 ceils by electropora- 
tion as described above. After 2 d of culture in complete Iscove's 
medium,  virus-containing supernatants were harvested, filtered 
through a 0.45-#m filter, and stored at - 70~  Virus stocks were 
assessed for gag p24 concentration using a commercial  antigen cap- 
ture ELISA (Coulter Immunology, Hialeah, FL) according to the 
manufacturer's instructions. The viral stocks were each normal- 
ized to 10 ng/ml of p24. Higher concentrations of virus were pre- 
pared by infecting H9 cells overnight  with the 10 ng/ml virus stocks 
from COS cells. The infected H9 cells were passaged in RPMI con- 
taining 10% FBS, 100 U/ml pen/strep, and 1 mM Hepes buffer 
(complete RPMI) for 15 d with changes of the culture medium 
every other day. Peak days of viral replication were determined by 
p24 ELISA and those culture supernatants were filtered and stored. 
The H9-generated HIV stocks were normalized to 250 ng/ml of 
pelletable virus. Pelletable virus was determined by microcentrifu- 
gation for 90 min at 15,000 g. Nonpelletable  p24 constituted "50% 
of the total p24 value in all the virus preparations. 
PBMC and Macrophage/Monocyte Isolation.  Human PBMC were 
obtained by Ficoll-Paque (Pharmacia-LKB,  Piscataway,  NJ) density 
gradient centrifugation of burly coats from normal commercial 
blood donors. To isolate monocytes and macrophages, 50-70  x 
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containing 20% FBS and 10% pooled human AB serum (Gemini 
Bioproducts, Calabasas, CA) in T25 flasks (Costar Corp.,  Cam- 
bridge, MA). Nonadherent cells  were removed  by rigorous washing 
with warm PBS. The adherent cells were further cultured for 3 
d in RPMI/20% FBS before infection. These adherent cell cul- 
tures contained more than 95% macrophages as identified by light 
microscopic  observation of nonspecific  esterase-stained  cultures (23). 
Unstimulated resting PBMC were cultured in complete RPMI con- 
taining 10% pooled human AB serum to avoid FBS-associated T 
cell activation. 
Infections and Cell Culture.  All infections were performed by in- 
cubating the cells overnight in 1.5-3 ml of a virus supernatant nor- 
malized to virion-associated p24 concentration ranging from 1 to 
250 ng/ml. 2-20  x  106 PBMC were infected freshly after isola- 
tion or after 2 d of stimulation with 4/~g/ml of PHA-P (Sigma 
Chemical Co., St. Louis, MO). After overnight infections, these 
cultures were washed four times in PBS and then recultured in 
4 ml of RPMI/10% human AB serum with (PHA-activated cul- 
tures) or without (unstimulated cultures) recombinant human IL-2 
added at 10 U/ml (Cetus Corp., Berkeley, CA) in 12-well plates. 
The unstimulated  cultures were activated at various times from 
I to 11 d later by adding a 2 x  solution of PHA-P and rlL-2. These 
cultures were incubated for 2 d, washed once, and returned to rlL-2 
supplemented RPMI/10% AB. Aliquots of culture supernatants 
were taken from all cultures every 2-4 d and 50%  of the media 
exchanged every fourth day. Infections of the immortalized T cell 
lines CEM, C8166, and H9 were performed analogously using 107 
cells and then culturing in complete RPMI/10% FBS. Every other 
day '-30% of the cells were removed and fresh culture medium 
was added to maintain a viable culture. Macrophage infections were 
performed overnight using 3 ml of 8 ng/ml p24 normalized viral 
supernatant in the T25 flask. The macrophages were then washed 
four times in PBS and cultured in RPMI/20% FBS with a 75% 
media exchange every third day. 
T Cell Clone Stimulation and Infection.  The influenza hemag- 
glutinin  (HA)-specific, CD4 § human T cell clone 103.13 was a 
generous gift of Wim VanSchutten (Immulogic, Palo Alto, CA) 
and was maintained by antigen stimulation every 2-3 wk with pep- 
tide antigen presented by mitomycin C-treated (Sigma Chemical 
Co.),  autologous EBV-transformed B cells. The culture medium 
contained 6% pooled human AB serum, and rlL-2 was added at 
5 U/ml 4 d after antigen stimulation. 2 wk after stimulation, the 
IL-2 was removed and the cells allowed to quiesce  overnight. 500,000 
cells were then infected using 10 or 250 ng/ml of p24 overnight 
and then washed four times. The infected cells were then stimu- 
lated with peptide antigen  and expanded in vitro with periodic 
culture  supernatants removed for p24 determination. 
TCIDso Studies.  Sextuplicate infections of 104 CEM cells, 104 
H9 cells, or 10  s PBMC from two different donors were performed 
using serial fivefold dilutions of viral supernatants starting at 100 
ng/ml of p24. The infected cultures were maintained in 200 #1 
of RPMI/10%  FBS in 96-well plates and visually inspected for 
cytopathic effect. Infected cultures were confirmed as positive by 
assaying 100 #1 of the supernatant for a p24 concentration activity 
two standard deviations beyond the residual input level on day 14 
for H9 and CEM, and day 21 for PBMC infections. The TCIDs0 
is the reciprocal of the dilution of a 100 ng/ml p24 viral superna- 
tant that results in infection of 50% of the wells. TCIDs0 values 
were calculated according to the method of Reed and Muench (24) 
by interpolation between the dilutions that bracketed the TCIDs0 
endpoint. 
Single-Cell Infectivity Assay.  This assay  was described  as the mul- 
tinuclear activation of a galactosidase indicator (MAGI) assay by 
Kimpton and Emerman (25). The HeLa-CD4- LTR-fl-gal cell line 
was obtained through the AIDS Research and Reference Program 
(Cat. #1470) and was maintained in complete Iscove's  medium with 
10% FBS. 1 d before infection, 7  x  103 cells were plated per well 
in a 96-well plate in 100 #1 media. The medium was then removed 
and replaced with 100 #1 of the virus stock at the indicated concen- 
tration of pelletable gag p24 for an overnight infection. Soluble 
CD4 was then added at a concentration of 1 #g/ml to prevent poten- 
tial viral spread and syncytium formation.  After a total of 40 h 
following infection the cells were nearly confluent. The superna- 
tant was aspirated and the cells were fixed for 5 min with 0.2% 
glutaraldehyde and 1% formaldehyde  in PBS. The wells were washed 
twice with PBS and 50 #1 of the fl-gal substrate was added (0.4 
mg/ml X-gal, 4 mM potassium ferrocyanide,  4 mM potassium fer- 
ricyanide, and 2 mM MgC12). The plates were incubated for 50 
rain at 37~  and then washed twice. Foci of infected blue cells 
were counted using the light microscope. Many loci consisting of 
two-four blue cells were observed, likely reflecting cell division 
events. Wells of uninfected cells did not contain any blue cells, and 
all infections were performed in triplicate using multiple dilutions 
of virus. 
Results 
Construction and Characterization of Proviral Vectors.  As sum- 
marized diagrammatically in Fig.  1 a,  the Nef-expressing 
HIV-1 used for these studies was a modification of the HXB2 
molecular clone pHXB2gpt  in which the premature stop 
codon in the nefgene was replaced with a portion of a cloned 
cDNA from an HIV-lmB-infected H9 cell line (26, 27). This 
repaired HXB2 clone, HXB Nef  + , has been completely se- 
quenced within the nefreading frame and contains four amino 
acid substitutions with respect to the published HIV LAI 
sequence (28) at positions 11 (V~I), 43 (A-~V), 64 (A--,-D), 
and 168 (K--~E) and one additional substitution with respect 
to the published HXB2 sequence (29) at position 14 (L--*P). 
None of the amino acid substitutions within Nef are unique 
to this molecular clone when the sequence is compared to 
other published Nef amino acid sequences  (30).  HXB Nef  + 
was mutagenized at the unique XhoI site in nef to create a 
frameshift (fs) mutant generating a stop codon 33 bases down- 
stream (HXB fs). The second nefmutant, HXB Astart, (ob- 
tained from M. Reitz, National Cancer Institute, Bethesda, 
MD), contains a ClaI site in place of the primary nef ATG 
as well as the unrepaired premature stop codon. The nefde- 
letion mutant, AN-term, was prepared by cleaving at the in- 
troduced ClaI site  and at the BgllI site in nef.  As HIV in 
the HXB2 background does not infect primary macrophages 
efficiently, the brain tissue-derived molecular HIV-1 clone 
YU-2  (31,  32)  was  utilized for the  macrophage infection 
studies.  The cloned YU-2 virus was modified by subcloning 
the entire BssHII-XhoI fragment from the pTZ vector into 
the HXB Nef  + vector described above, thus generating YU- 
2b. A nefframeshift  mutant of this virus was then made at 
the XhoI site (YU-2b fs). All of these HIV proviral DNA 
plasmids, except HXB2, were transfected by electroporation 
into COS-7 cells, and detergent lysates were assessed for Nef 
expression by immunoblotting with a mouse anti-Nef mono- 
clonal antibody raised against recombinant BH10 Nef (Fig. 
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codon in HXB2 was repaired as previously  published (26, 27), creating 
HXB Nef  +  . The frameshift  mutants were  created  by cutting at the unique 
XhoI site, blunting with Klenow,  and religating. The HXB Astart con- 
tains a ClaI site in place of the start codon (M. Reitz, NCI), and HXB 
AN-term contains a deletion delimited by the introduced ClaI site and 
the BgllI site. YU-2b is a recombinant  containing  the entire  BssHII-XhoI 
fragment from YU-2 in the HXB Nef  + plasmid. (b) Nef is expressed  from 
the HXB Nef  + and YU-2b proviral  constructs. The proviral HIV con- 
structs described  in A were transfected  into COS-7 cells and cell lysates 
were electrophoresed  in a 10% acrylamide  gel. The gel was blotted and 
then incubated with a mouse anti-Nef monoclonal antibody  generated 
against recombinant BH10 Nef. Bands corresponding to Nef appear at 
,'o27  and 28 kD only in the lanes containing  lysates  from the transfections 
of proviral HIV with intact nef reading frames. 
1  b).  As  expected, both  the  HXB  Nef  +  and  the YU-2b 
transfections produced detectable levels of the Nef protein. 
The difference between the migrations of the two Nef spe- 
cies is likely due to a 10-amino acid insertion in the 5' end 
of the YU-2 nefthat is included in the YU-2b recombinant. 
In contrast, the lysates from the nefmutant transfections did 
not demonstrate any detectable Nef-specific immunoreactive 
product. The nefframeshift mutants would be expected to 
have generated a 6-kD Nef polypeptide too small to identify 
in these polyacrylamide gels.  However, both the Nef  § and 
Nef-  HIV  proviral DNA  transfections generated normal 
titers of viral particles as measured by gag p24 ELISA. Fur- 
thermore, immunoblotting the cell lysates with an anti-HIV 
human antisera demonstrated detectable HIV gag p24 and 
HIV envelope glycoproteins in all  cases (not  shown). 
Infection of Transformed T Cell Lines.  To confirm the in- 
fectious properties of these viral stocks, human T  lympho- 
blastoid cell lines were infected with the HXB Nef  § as well 
as the three nefmutant viruses using 10 ng/ml of gag p24 
from the COS-7 cell transfections. The culture supernatants 
were subsequently monitored for viral production by p24 
ELISA. As shown in Fig.  2, all of the viruses were compe- 
tent to replicate in CEM,  C8166,  and H9 cells.  There ap- 
peared to be no consistent difference among the infections 
in terms of kinetics or magnitude of viral replication. These 
findings are in agreement with earlier observations, which 
indicated that Nefis a dispensable gene product for viral repli- 
cation in  transformed human T  cell lines (11, 20). 
Infection of  Primary  PBMC.  Primary PBMC were isolated 
from a healthy donor and then activated with PHA-P for 
2 d. These cells were then infected with the Nef  + and Nef- 
HXB-based viruses generated from COS-7 cell transfections 
and placed into IL-2 supplemented medium.  As shown in 
Fig.  3 a, the HXB Nef  + virus demonstrated increased viral 
replication as compared with the frameshift and Astart nef 
mutants in these mitogen-activated PBMC cultures. To more 
closely approximate possible in vivo conditions of HIV-1 in- 
fection, unstimulated freshly isolated PBMC from the same 
donor were also infected with the Nef  + and Nef-  viruses 
and then placed into culture without mitogen. 1 or 4 d later, 
these cultures were activated with PHA-P and IL-2 and the 
culture supernatant was monitored for virus production by 
the p24 ELISA. Under  these conditions a dramatic differ- 
ence in  replication between  the  Nef  +  and  Nef-  isogenic 
viruses was observed. Specifically, the three nefmutant viruses 
displayed little or no detectable growth at the time of peak 
viral replication in  the  HXB  Nef  +  infection and  did  not 
begin to detectably replicate until 3 wk after infection (Fig. 
3, b and c). In other experiments, the PBMC were activated 
7 or 11 d  after infection with similar results (not shown). 
Given the propensity of HIV to mutate in vitro, it was pos- 
sible that the HXB fs and Astart nefmutants may have reverted 
to wild type nefto generate the late viral growth. To address 
this possibility, we infected unstimulated PBMC from an- 
other donor with the nefdeletion mutant virus (AN-term). 
Fig.  3 d shows delayed but eventual growth of this mutant, 
suggesting that reversion is not the proximal cause for the 
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Figure  2.  Immortalized  T cell lines replicate HIV equally  well in the 
presence or absence of Net. Three immortalized,  long-term  cultured  cell 
lines: CEM (a), C8166 (b), and H9 (c) were infected  with either HXB 
Net  §  , HXB fs, HXB Astart, or HXB AN-term, as indicated. All infec- 
tions were done overnight  with COS-7 cell-derived  virus stocks  normal- 
ized to 10 ng/ml of gag p24. Every  3-4 d the tissue culture medium  was 
changed, the cells split 1:1, and the accumulated  p24 concentration  in the 
supernatant was assessed using a p24 ELISA. 
delayed growth exhibited by the Net-  viruses. In fact, in ex- 
tended PBMC cultures, the growth of the Net-  virus, al- 
though very delayed, can approach that found with wild type 
virus (not shown). To date,  this striking difference in viral 
replication kinetics between Net  + and Net- viruses has been 
repeated using primary PBMC from 10 random donors. Thus, 
infection of unstimulated PBMC with HIV and subsequent 
activation provide for a robust biological phenotype that re- 
veals a positive role for Net in accelerating virus replication 
in primary PBMC. 
Infection of Primary Macrophages.  To determine whether 
HIV-1 Net might also positively contribute to viral replica- 
tion  in  a  different  host  cell,  primary  peripheral  blood 
monocyte-derived macrophages were purified by adherence 
to plastic and then infected 6 d later with macrophage-tropic 
YU-2-derived Net  + and net frameshift viruses, as well as the 
HXB  Net  §  virus.  As expected,  the T  cell-adapted HXB 
Net  + virus replicated poorly in these adherent macrophage 
cultures (Fig. 4 a). In contrast, the YU-2b Net  + virus grew 
quite well, establishing a persistent infection that produced 
virus over the entire 1-mo culture period. In the case of the 
YU-2b nefframeshift mutant, viral infection was established; 
however, the magnitude of gag 1024 production was reduced, 
suggesting that the spread of HIV infection in vitro was less 
efficient. This finding of reduced but not delayed viral produc- 
tion has been reproducibly demonstrated using monocyte- 
derived macrophages from five different donors. However, 
infection of unstimulated PBMC with the Net + and Nef- 
YU-2b viruses demonstrated the delayed kinetics of replica- 
tion for the nefmutant as previously observed with the HXB- 
derived virus infection of PBMC (Fig. 4 b). These findings 
may highlight the differences in the viral infection parameters 
active in tissue culture models of PBMC and macrophage 
infection, and are consistent with the observations that the 
capacity to infect macrophages is dependent on the differen- 
tiation  state  of the  cells,  becoming  less efficient  during 
prolonged culture (33-35).  Thus, the capacity of the Net- 
virus infection of macrophages to eventually achieve the high 
level of viral replication observed in PBMC infections is re- 
duced due to the extended culture. 
Infection of an Antigen-specific CD4 + T  Cell  Clone.  The 
capacity of Net to enhance viral growth in an infected human 
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Figure 3.  HIV replication in un- 
stimulated  primary  PBMC  is  ac- 
celerated in the presence of Nefafter 
lectin  activation.  (a) PBMC were 
isolated from healthy donors and ac- 
tivated with PHA-P before infection 
with 10 ng/ml of the indicated HIV 
stocks  derived  from  COS-7  cell 
transfections. The virus was washed 
off and then the PBMC placed into 
IL-2-supplemented  media.  Every 
3-4  d  one  half  of  the  culture 
medium was exchanged with fresh 
1I.-2 media and the supernatant was 
assayed for p24 content.  (b, and c) 
Unstimulated  PBMC were infected 
directly after isolation with the in- 
dicated viruses. The following day, 
the cells were extensively washed 
and then activated immediately (b) 
or 4 d later (c) with PHA-P and IL-2 
and cultured as described. (d) PBMC 
from another  donor were infected 
with the indicated viruses, including 
the HXB AN-term deletion  mu- 
tant, and cultured as above. PBMC 
infections  from  over  10  different 
donors  have generated  analogous 
results,  using  HIV prepared  both 
from COS-7 cell transfections and 
HIV prepared from H9 cells infected 
with COS-7 virus  stocks. 
T cell following more physiological activation with antigen 
was  addressed  using  a  CD4 +,  influenza  hemagglutinin- 
specific T  cell clone restricted by HLA-DR4.  The clone is 
routinely passaged in vitro by periodic antigen stimulation 
using peptide antigen and autologous antigen presenting B 
cells followed by IL-2-mediated cell proliferation.  Three weeks 
after antigen  stimulation,  the clone was allowed to enter a 
state of growth arrest by removing IL-2, and the cells were 
then infected with either HXB Nef  + or nefframeshift HIV 
generated from H9 cell infections at  two virus concentra- 
tions, 10 ng/ml and 250 ng/ml of gag p24. The clones were 
then restimulated with antigen and expanded in vitro,  and 
the culture supernatant was monitored for virus production. 
The low-dose HXB Nef + infection resulted in an 8- to 28- 
fold increase in virus production at all time points assayed, 
while the high-dose infection resulted in very low levels of 
replication  enhancement  (Table  1). These data demonstrate 
that  an antigen-specific T  celt clone infected at a low mul- 
tiplicity of infection (MOI) and subsequently stimulated with 
antigen produces greater quantities of virus in the presence 
of an intact nef reading  frame during  one cycle of antigen 
restimulation.  However,  this  viral  growth  advantage  is 
significantly reduced  at high  multiplicities  of infection. 
Multidose Infection of  Primary PBMC.  The observation of 
an MOI dependence on Nef function in the T cell clone in- 
fections prompted us to expand upon our initial  observations 
in the unstimulated PBMC infections. In these studies, we 
infected 20  x  :[06  PBMC with two dilutions of HXB Nef  + 
and HXB fs. The high dose of virus, 250 ng/ml of p24, ex- 
hibited only up to a 15-fold increase in gag p24 over the cul- 
ture period,  while the lower dose exhibited the more dra- 
matic  accelerated  replication  kinetics  typical  of  PBMC 
infections  with  Nef  + virus  (Table  2).  In  experiments  not 
shown, PBMC were infected with as little as 1 ng/ml of gag 
p24, in which case the nefmutant  HIV would occasionally 
fail to establish an infection whereas the Nef  + virus would 
eventually establish a fulminant in vitro infection. Thus, as 
with the antigen-specific T cell clones, these results demon- 
strate an MOI dependence on the capacity of Nef to enhance 
viral replication  in primary PBMC. 
Tissue Culture Infectious Dose (TCIDso) Studies.  The pos- 
sibility that the differential replication kinetics of Nef  + and 
Nef- HIV might directly result from intrinsic differences in 
the infectivity of the Nef  + and Nef- virus preparations was 
addressed by determining TCIDs0 values. Two immortalized 
T cell lines and PHA-activated PBMC from two donors were 
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Figure 4.  HIV replication  in macrophages is increased  in the presence 
of Nef. (a) Monocytes  and macrophages were isolated from the PBMC 
of healthy  donors  by adherence  to plastic  and multiple  washings.  The cells 
were infected  after  6 d of adherence culture and were >95% nonspecific 
serine esterase  positive  at the time  of  infection.  The cultures  were  infected 
overnight  with the indicated  macrophage-tropic  YU-2-derived virus stocks 
using 8 ng/ml of gag p24.75% of the media was exchanged  every  third 
day and the accumulated  concentration  of p24 was assessed  at those  times. 
These are representative  data from  macrophage  infections  of five  indepen- 
dent donors. (b) PBMC were infected  with the indicated  YU-2 viruses 
as described  in the legend  to Fig. 3 and activated  just after  infection.  The 
virus stocks  utilized  were prepared from  COS-7 cell transfections.  Similar 
results have  been obtained  using  YU-2b and YU-2b fs HIV prepared from 
PBMC infections. 
infected with both COS-7 cell- and H9-derived HIV in serial 
fivefold dilutions. As shown in Table 3, TCIDs0 values were 
reduced from 1.5- to 5.6-fold for infections with the two 
Nef- viruses as compared with HXB Nef  § . The reduction 
in TCID50 was more notable in the PBMC infections, but 
was also apparent in both H9 and CEM cell infections. In 
another experiment, H9 and C8166 cells were infected, but 
only the infections of H9 cells showed a reduced TCID50 
(not shown). Thus, a positive effect on viral replication can 
be demonstrated for Nef in some but not all immortalized 
T cell lines in the TCID50 assay. However, as described above 
(Fig.  2),  there appears to be no consistent difference in the 
viral replication kinetics in the same immortalized cell lines. 
These data suggest that properties inherent to virus infec- 
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tion and propagation in transformed cell lines may mask a 
positive biological function for the nef gene under all but 
the most limiting conditions of infection. This is in contrast 
to the more broadly defined positive effect that Nef exerts 
during infection of primary lymphocytes and monocytes over 
a wide range of viral MOI. 
Single-Cell Infection  Analysis.  The definition of reduced 
TCIDs0  values  for  Nef-  HIV  could  either  indicate  that 
Nef- virus is inefficient at initially infecting target cells or 
that the subsequent in vitro spread  of virus, necessary  for 
a positive TCID culture, is impaired in the Nef-  virus in- 
fections.  To further characterize  the mechanism of Nef ac- 
tivity we utilized a single-cell  infection assay developed by 
Kimpton and Emerman (25). The HeLa-CD4 indicator cell 
line is stably transfected with/3-gal under the control of the 
HIV-1 LTR and is strictly dependent upon tat expression, 
provided by successful infection with HIV, for 3-gal expres- 
sion and activity. After a 40-h infection of a monolayer in 
a microtiter well, the X-gal substrate solution was added and 
the number of  blue cells scored by light microscopy. The assay 
is quite reproducible and behaves linearly over a reasonable 
counting range of 10-400 infected cells. During the period 
of infection and tat-expression cell division is occurring; thus, 
equally infected daughter cells are apparent but are only scored 
once. As shown in Fig.  5 a, the H9-derived Nef  + HIV in- 
fected five to six times as many cells as either nefmutant HIV 
at a concentration of 50 ng/ml of pelletable gag p24.  Simi- 
larly, a four- to eightfold enhancement in infectivity has also 
been observed using Nef  § and Nef-  HIV generated through 
transfection of COS-7 cells (not shown). Thus, the infection 
events leading to Tat production in the first round of infec- 
tion are facilitated in the presence  of intact nef. 
PBMC Infection  Normalized  to Infectivity.  Given the ob- 
servations from both the TCID50 studies and the single-cell 
infectivity assay that Nef  + HIV is as much as six times more 
infectious than Nef- HIV, it was possible that the initial in- 
fectivity difference alone accounted for the differential repli- 
cation kinetics presented in Fig. 3. To address this issue, un- 
stimulated PBMC were exposed to 4-fold and 16-fold more 
Nef- HIV, and then activated and monitored for virus repli- 
cation over  time. The 16-fold excess of Nef-  HIV would 
ensure that these infections contained even greater numbers 
of initially infected cells than the Nef  + infection, based on 
both the single-cell infectivity assay and the TCID50 assay. 
As shown in Fig.  5 b, under both of these conditions the 
production of virus in the Nef- virus infection appreciably 
lagged behind the infection with Nef  + HIV. Interestingly, 
the earliest time points after infection, although only demon- 
strating p24 in the pg/ml range, showed comparable initial 
virus production from both the Nef  + and Nef- infections. 
Together, these observations suggested that the virus pro- 
duced from the infected PBMC was also differentially infec- 
tious depending on the presence or absence of Nef. To assess 
this, the HIV produced from the PBMC infections was also 
analyzed for infectivity in the HeLa/3-gal single-cell  infec- 
tivity assay. Fig.  6 demonstrates that HIV produced from 
PBMC infection with Nef  + HIV is 13-17  times more in- 
fectious than that produced from Nef-  HIV PBMC infec- Table  1.  Infection of an Antigen-specific T  Ceil Clone with Nef  + vs. Nef-  HIV Results in More Efficient Viral Replication after 
Activation with Antigen 
gag p24 
Days after 
Virus dose*  infection  HXB Nef  +  HXB fs  Fold Nef induction~ 
10 ng/ml 
250 ng/ml 
ng/ml 
6  6.6  0.5  13.9 
8  69.4  3.1  22.5 
10  289  10.3  28.0 
13  934  54.9  17.0 
16  1258  78.2  16.2 
19  856  70.5  12.1 
22  495  61.3  8.1 
6  10.3  9.9  1.0 
8  19I  72.3  2.6 
10  1005  403  2.5 
13  4190  120t  3.5 
16  1625  1082  1.5 
19  1462  926  1.6 
22  976  776  1.3 
* An influenza hemagglutinin-specific  CD4 + T cell clone (0.5  x  106 cells) was infected  with HIV on day 0 with either 10 or 250 ng/ml of gag 
p24, employing  either HXB Nef+ or the HXB nefframeshift mutant, HXB fs, generated from H9 cells. Virus was washed off the cells with PBS 
on the following  day and the cells were activated  with peptide antigen presented  by autologous B cells. I1-2 was added to the media 4 d later. Viral 
supernatant samples were taken on the indicated days after infection and the quantity of gag p24 determined by ELISA. 
* Fold Nef induction is the ratio of gag p24 from the HXB Nef  § infection  vs. the HXB fs infection. 
tion. This differential infectivity of PBMC-derived HIV per- 
sists over the entire culture period of virus production. Thus, 
the capacity of Nef to enhance viral replication in primary 
cells is due to its capacity to facilitate initial HIV infection 
as well as  subsequent virus spread in culture. 
Discussion 
The results presented in this report demonstrate that HIV-1 
nef significantly augments  the in  vitro replication of two 
different molecular clones of HIV upon infection of two nat- 
ural target cells of HIV-I: primary T lymphocytes and mac- 
rophages. This positive Neffunction is most pronounced when 
unstimulated freshly isolated PBMC are infected and then 
subsequently activated with mitogen. Furthermore, this func- 
tion is related to the multiplicity of viral infection, with the 
lowest MOI demonstrating the greatest enhancement of  viral 
replication in  the Nef  + virus.  The MOI-dependence indi- 
cates  a  potential  infectivity difference between  Nef  §  and 
Nef- HIV that is supported by reduced TCIDs0 values and 
reduced infectivity titers in a single-ceU infectivity assay with 
Nef- virus. Together, these data suggest that nefacts in the 
cells producing virus to increase the infectivity of progeny 
viral particles. 
Interestingly, the described positive function of Nef was 
not definable through conventional infection at moderate MOI 
of numerous immortalized T cell lines (Fig. 2). In sharp con- 
trast to these results, several groups have shown negative effects 
of Nef on virus replication employing various immortalized 
T  cell lines (7,  9,  10).  However, other investigations have 
shown, in agreement with our studies, that the presence of 
intact nefresuhed in little or no difference in viral replication 
in immortalized T cell lines (5, 11). In one case, Kim et al. 
(11) utilized the same ceils and the same molecular clones 
of HIV as in the earlier studies, and were still unable to dem- 
onstrate a negative effect on replication. Interestingly, this 
group observed a moderate positive effect upon infection of 
activated PBMC.  In this regard, de Ronde et al.  (36) have 
transfected Nef  + and Nef- proviral HIV constructs into ac- 
tivated PBMC and also demonstrated a moderate positive effect 
on virus replication. Similarly, Terwilliger et al.  (37) have 
shown differences in the growth of HIV containing a recom- 
binant of the Eli allele of Nef in the HXB2 background in 
activated PBMC. In that report, however, there was no de- 
tectable growth of the Nef- variants in activated PBMC at 
any time after infection. This is in contrast with our data, 
which show only a substantial delay in viral replication in 
the absence of Nef at the lowest MOI and near wild type 
replication of a Nef-  variant at the highest MOI.  In this 
report we expand upon these earlier observations of Nef func- 
108  HIV-1  Nef Enhances HIV Infection and Replication Table  2.  Nef-mediated Enhancement  of HIV Replication Is MOI Dependent in  Unstimulated PBMC Infections 
gag  p24 
Days  after 
Virus  dose*  infection  HXB  Nef  §  HXB  fs  Fold Nef induction* 
10  ng/ml 
250  ng/ml 
ng/ml 
11  0.034  ND  s 
13  0.70  0.012  58 
15  18.6  0.021  885 
17  59.1  0.12  492 
19  258  2.8  92 
24  632  30.0  21 
28  217  69.7  3.1 
11  1.2  0.28  4.1 
13  82.1  7.4  11 
15  313  20.5  15 
17  423  45.0  9.4 
19  288  58.2  4.9 
24  359  264  1.3 
28  390  503  0.8 
* Unstimulated PBMC (20  x  106 cells) were infected  with the indicated  concentration of HIV,  employing either HXB Nef+  or the HXB nef 
frameshift  mutant,  HXB fs, generated  from H9 cells. Virus  was washed  off the cells with PBS on the following day and the cells were activated 
with PHA/IL-2 on day 5. Viral supernatants samples were taken on the indicated days after infection and the quantity of gag p24 determined by ELISA. 
* Fold Nef induction is the ratio of gag p24  from the HXB Nef+  infection  vs.  the HXB fs infection. 
$ ND,  not detectable. 
Table  3.  Limiting  Dilution  Infection of H9,  CEM,  and PBMC Demonstrate a Reduction  in Infectivity for Nef-  HIV. 
TCIDs0  value*  at  100  ng/ml p24  (Fold reduction*) 
Target  cells  Source  of virusS  HXB  Nef  §  HXB  AN-term  HXB fs 
H9  COS  transfection  12.6  ￿  10  3  4.6  ￿  10 3 (2.7)  NTII 
H9 infection  2.5  ￿  103  1.4  ￿  103  (1.8)  1.1  x 
CEM  COS  transfection  8.4  ￿  103  1.7  x  103  (4.9)  NT 
H9 infection  2.5  ￿  103  0.90  x  103  (2.8)  0.75  x 
PBMC  COS  transfection  2.5  x  103  1.7  x  103  (1.5)  NT 
Donor  A  H9 infection  7.5  ￿  102  2.2  x  102  (3.4)  2.0  x 
PBMC  COS  transfection  6.7  x  103  1.3  x  103  (5.1)  NT 
Donor  B  H9 infection  1.3  x  102  0.29  x  102  (4.5)  0.23  x 
10  3 (2.3) 
10  3 (3.3) 
102  (3.8) 
lO~ (5.6) 
* The TCIDs0 value is the reciprocal of the dilution of 100 ng/ml gag p24 supernatant  that results in the infection  of 50% of the wells containing 
target cells.  104 (H9 and CEM) or 105 (PHA-activated  PBMC) target cells were infected  in sextuplicate  and cultures  were scored positive  if the 
p24 concentration 14 d (H9 and CEM) or 21 d (PBMC) after infection was greater  than 2 SD away from background.  50% endpoints  were interpo- 
lated  when necessary (24). 
Fold reduction in TCIDs0  value of nef mutant  viral  stock  as compared  with the HXB Nef  + viral stock  on the same target cells. 
S HIV stocks analyzed for infectivity were isolated from COS-7 cell transfections  of proviral  plasmid DNA 2 d after transfection  and from H9 cells 
infected  with the COS-7 cell virus  stocks  11  d (Nef+),  13 d  (fs) or 15  d  (AN-term) after  infection. 
II NT,  not tested. 
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Figure  5.  (a) Viral infectivity is reduced in Nef-  viral stocks of H9 
cells. Viral infectivity was quantified in a single-cell infection assay utilizing 
a HeLa-CD4 cell line stably transfected with B-gal under the control of 
a Tat-dependent  HIV-1 LTR. Cells in microtiter plates were infected with 
H9-produced HXB Nef  § and the two nefmutants, neffs and AN-term, 
at 50 and  10 ng/ml of pelletable gag p24.  40 h after infection  the cells 
were incubated  with the ~-gal substrate  X-gal, and the number of in- 
fected cells expressing Tat was scored by light microscopy. Call division 
events over the infection period resulted in daughter cells each expressing 
Tat and were counted as one infection event. Each infection was performed 
in triplicate and the standard deviation of the triplicate average is indicated 
above the bar. The neffs mutant was 4.4-fold less infectious and the AN- 
term mutant 6.3-fold less infectious  than the Nef  + virus at 50 ng/ml of 
p24.  (b) PBMC infection  infection  normalized  to viral infectivity  with 
a 16-fold excess of Nef- HIV demonstrates  delayed viral replication  ki- 
netics. Unstimulated PBMC (20  x  106 cells) were infected with 4 ng/m] 
of HXB Nef  § , 16 rig/m1 HXB neffs,  or 64 ng/ml of HXB neffs as de- 
scribed in the legend to Fig. 3.  1 d after infection  the PBMC were acti- 
vated with PHA and the culture supernatant  monitored for the produc- 
tion of virus over time by gag p24  ELISA. 
tion in primary cells and provide evidence that the basis for 
the positive effect of Nef on viral replication is due to the 
increased infectivity of Nef  + viral particles. We now postu- 
late that  the lack of a Nef-associated replication phenotype 
in immortalized T  cell lines is due to the greater ease with 
which HIV, even the less infectious Nef-  HIV, can spread 
in these highly permissive culture conditions  using tissue- 
culture adapted HIV strains. Of note, however, are the differen- 
tial effects of Nef on infection  of both H9 and CEM cells 
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Figure  6.  HIV produced dur- 
ing PBMC infection  with Nef  § 
HIV is more infectious than that 
produced  from  PBMC  infected 
with Nef defective HIV per ng of 
gag p24. Viral supernatants  were 
harvested after infection of PHA- 
activated PBMC with 8 ng/ml of 
COS-7 cell produced HXB Nef  + 
and neffs HIV on day 13 after in- 
fection.  At this  late  time point 
there is comparable viral produc- 
tion in both cultures. The HeLa- 
CD4-LTR-B-gal cell line was then 
infected with either 32 or 16 ng/ml of each viral supernatant  as described 
in the legend to Fig. 5, and blue loci were counted after 40 h of infection. 
The virus derived from the Nef  + PBMC infection  was 13.5 times (at 32 
ng/ml) or 17.5 times  (at  16 ng/ml) more infectious  than  virus derived 
from the nef mutant PBMC infection. 
observed in the presented TCIDs0 studies. Thus, at extreme 
limiting dilution of virus some immortalized T cell lines can 
demonstrate a replication advantage for Nef  + HIV infection. 
The nucleotide sequence of nef varies  considerably from 
isolate to isolate, and some variants might  conceivably en- 
code dysfunctional gene products (30, 38). Of particular note 
is a repetitive sequence of variable length near the 5' end of 
the nefgene, beginning at nucleotide 8464 (30). The length 
of this sequence depends on the isolate and can give rise to 
a 2-14-amino  acid insertion  in Net'.  The HXB Nef  + HIV 
used in these studies does not contain such an insertion; how- 
ever, the YU-2b recombinant contains a 10-amino acid in- 
sertion  in this region.  The capacity of the YU-2b recom- 
binant  nef also to  enhance  viral replication  in PBMC and 
macrophages demonstrates that even a 10-amino acid inser- 
tion in this region does not impair  the capacity of Nef to 
mediate enhanced replication.  However, in analyses  of Nef 
activity that are based on cell-surface CD4 down-regulation, 
dysfunctional alleles of nefhave been identified (18, 39). The 
infectivity and replication assays described in this report can 
be harnessed  to determine whether  the capacity of Nef to 
down-regulate CD4 expression is related to the increased in- 
fectivity of Nef + HIV  particles.  Moreover,  an  analysis  of 
naturally occurring Nef isolates for functional capacity in vitro 
should reveal whether dysfunctional nefalleles are present in 
HIV-infected people.  Given  the  reduced  capacity of Nef- 
defective virus to infect and replicate, the presence of defec- 
tive nef genes may play a role in determining  the variable 
pathogenic  courses observed in HIV-infected people. 
Now with the consistent demonstration of a positive rather 
than a negative effect of Nef on the infection and replication 
of HIV in multiple cell types, including primary PBMC, pri- 
mary macrophages, and antigen-specific T cell clones, as well 
as the positive effects  of Nef on SIVmac replication  in vivo 
in monkeys, one can begin to determine the precise mecha- 
nism of the positive regulatory effects of Nef. It is possible 
that the increase in infectivity is related to the apparent ca- 
pacity of Nef to modulate T  cell activation and thymocyte 
ontogeny (18,  40).  In  the case of the Nef-transgenic mice, 
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creased cell surface CD4 expression, and elevated intracellular 
Ca  2+ flux after anti-CD3 treatment.  These two observations 
may be related as studies in T cell clones have demonstrated 
an increased sensitivity to TCR-mediated activation in the 
absence of CD4 (41), presumably due to the dissociation of 
CD4 from the tyrosine kinase p56  lck (42, 43).  In this regard, 
preliminary results were presented demonstrating a dissocia- 
tion between CD4 and p56  lck in Nef-expressing CEM cells 
(44). Thus, it is possible that a Nef-induced dysregulated in- 
tracellular activation environment might be more conducive 
to replication and the production of infectious HIV. How- 
ever, the data presented herein demonstrate a broadly defined 
function of Nef that can be observed in multiple cell types, 
including macrophages that lack p561cL Most interestingly, 
the transfection of COS cells, a cell line which expresses nei- 
ther CD4 or p56 ~ck, results in Nef  § HIV particles which are 
more infectious  than  Nef-  HIV in both  the TCID50  and 
single-cell infectivity assays. Thus CD4 expression, per se, 
is not absolutely required for Nefomediated enhancement of 
viral infectivity. 
We feel that our results argue against a mechanism of Nef 
activity that is strictly dependent upon a particular cellular 
environment  or upon a specific cellular process, e.g., T  cell 
activation.  In fact, although  the most pronounced effect of 
Nef was demonstrated by exposing unstimulated cells to virus 
and subsequently activating these cells, we have not yet une- 
quivocally established that resting cells are truly infected be- 
fore activation. Previous reports have defined the capacity of 
resting T  cells to be infected based on DNA PCR for evi- 
dence of early products of reverse transcription (45-47). How- 
ever,  two groups have subsequently shown the presence of 
such partial reverse transcripts within purified viral particles 
(48, 49),  and this may have confounded the interpretation 
of the earlier PCR-based analyses  of resting  cell infection. 
In our DNA PCR analysis,  we observed no evidence of re- 
verse transcription beyond the level that can be defined within 
the viral particles that are simply absorbed to cell surface mem- 
branes (our unpublished observations). Rather, we interpret 
the more pronounced positive effects of Nef in this  tissue 
culture setting to be due to a relatively inefficient infection 
process, which is more dependent upon intact Nef function 
for initial infection and viral amplification during the subse- 
quent  rounds  of infection. 
As the HeLa ~-gal single-cell infectivity assay models only 
a portion of the HIV replication cycle, it defines a temporal 
restriction  to  Nef function  within  the  replication  cycle. 
Specifically, the results from the assay indicate that either the 
particles  produced  from  cells  infected or  transfected with 
Nef  + HIV are intrinsically more infectious, or that the post- 
binding events leading to Tat expression are facilitated in the 
case of Nef +  HIV  infection.  As  the  Nef protein  has  not 
been found within purified virions and as tat and nefexpres- 
sion are concomitant in the newly infected cell (3), we pre- 
dict that Nef most likely exerts its function within the virus- 
producing cells. Most simply, we speculate that Nef acts in 
the virus-producing cells to create a more highly infectious 
viral particle, perhaps by increasing  the efficiency of gpl20 
incorporation into the viral membrane or in some other way 
affecting the assembly of complete and fully infectious viral 
particles.  Thus, a careful analysis of the composition of Nef  + 
and Nef-  HIV particles  is warranted. 
Although we have shown that CD4 expression is not re- 
quired for Nef-mediated enhancement of viral infectivity, it 
is possible that the ability of many HIV-1 nefgenes to down- 
regulate cell surface CD4 expression (16-18) may also con- 
tribute to the production of more highly infectious viral par- 
ticles.  Nef-mediated reduction of CD4 from the cell surface 
may result in a greater pool of envelope glycoproteins that 
are not associated with CD4 and that may, therefore, be suc- 
cessfully incorporated into the membranes of budding viral 
particles.  In  the  absence  of  Nef-mediated  CD4  down- 
regulation,  the  viral  particles  would  contain  a  decreased 
number of envelope glycoproteins in the viral envelope and, 
hence, would be less infectious (50).  Thus,  the capacity of 
Nef to mediate CD4 down-regulation may be important in 
the production of infectious HIV. Alternatively, these func- 
tions of Nef may be distinct. We can now compare the genetic 
determinants  of CD4 down-regulation  and increased viral 
infectivity by Nefas a means of addressing this issue. Interest- 
ingly, HIV-1 vpu has also been shown to affect CD4 expres- 
sion by mediating the degradation of CD4 bound to newly 
synthesized gp160 in the endoplasmic reticulum (51). Thus, 
HIV-1 appears to regulate cell surface CD4 expression via 
a multiple gene strategy that emphasizes the importance of 
regulating  CD4 receptor  expression in the viral life cycle. 
As previously noted,  infection  of rhesus  monkeys with 
Nef  +  and  Nef-deleted SIVmac demonstrated  the  establish- 
ment of significantly higher levels of viral burden, a greater 
extent of viral replication,  and virus-induced pathogenicity 
in animals infected with the Nef  + virus (21). Moreover, the 
data from that  study demonstrated  a strong selective pres- 
sure for reversion to a functional nefgene, which correlated 
with an increased in vivo viral burden. The authors inferred 
that the in vivo replication of SIV must be enhanced in the 
presence of an  intact  or reverted nef gene.  Curiously,  the 
authors were not able to demonstrate any clear enhancement 
in viral replication through infection of activated primary ma- 
caque PBMC, even at low MOI. In view of our results, in- 
fection  of unstimulated  macaque  PBMC  with  Nef  §  and 
Nef-  SIV  might  have  been  more  revealing.  We  predict 
that Nef- SIV, like Nef- HIV, would be less infectious than 
Nef  +  virus,  and  surmise  that  this  decrease  in  infectivity 
could greatly debilitate viral spread in vivo. Thus,  a seem- 
ingly minor 5- to 10-fold decrease in infectivity of the Nef- 
virus might  result in dramatically reduced viral spread and 
pathogenicity in an in vivo environment  where it was also 
opposed by an antiviral  immune response.  In parallel  with 
the SIV model, we propose that  HIV-1 Nef may function 
in vivo to increase viral infectivity and viral burden in HIV- 
infected humans, and that this would be linked to viral patho- 
genesis.  In support of this,  the SCID-Hu mouse model of 
HIV infection has yielded preliminary results confirming a 
greater in vivo viral burden and more accelerated pathogenic 
111  Miller  et al. consequences as a result of infection with a Nef  + HIV in 
the absence of a significant immune response (52). Given these 
pathologic and viral replication results in model systems,  it 
is possible that specific therapeutic approaches designed to 
inhibit H1V-1 Nef function in vivo may one day be of value 
in the treatment of HIV-1 infected people. The definition 
of reproducible tissue culture assays for Nef augmentation 
of viral replication provide an important starting point for 
the development of potential therapeutic agents. 
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